EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery

Ilaria Colombo iD, Katherine Karakasis, Sneha Suku, Amit M Oza

Cancers · 16.06.2023 · 15 (12) · 3220

DOI: 10.3390/cancers15123220 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.06.2023. Verfasst von Ilaria Colombo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Via A. Gallino, 6500 Bellinzona, Switzerland. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A deep understanding of the tumor microenvironment and the recognition of tumor-infiltrating lymphocytes as a prognostic factor have resulted in major milestones in immunotherapy that have led to therapeutic advances in treating many cancers. Yet, the translation of this knowledge to clinical success for ovarian cancer remains a challenge. The efficacy of immune checkpoint inhibitors as single agents or combined with chemotherapy has been unsatisfactory, leading to the exploration of alternative combination strategies with targeted agents (e.g., poly-ADP-ribose inhibitors (PARP)and angiogenesis inhibitors) and novel immunotherapy approaches. Among the different histological subtypes, clear cell ovarian cancer has shown a higher sensitivity to immunotherapy. A deeper understanding of the mechanism of immune resistance within the context of ovarian cancer and the identification of predictive biomarkers remain central discovery benchmarks to be realized. This will be critical to successfully define the precision use of immune checkpoint inhibitors for the treatment of ovarian cancer.

Schlagwörter

Stichwörter der Autor:innen

anti-PD-1/PD-L1immune checkpoint inhibitorsimmune therapyovarian cancerpredictive biomarkerstumor microenvironment

Autor:innen und Institutionen

  • Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Via A. Gallino, 6500 Bellinzona, Switzerland.
  • Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON M5G 2M9, Canada.

ORCID-Profile: Ilaria Colombo

Zitieren

APA

Colombo, I., Karakasis, K., Suku, S., & Oza, A. M. (2023). Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery. Cancers, 15(12), 3220. https://doi.org/10.3390/cancers15123220

Vancouver

Colombo I, Karakasis K, Suku S, Oza AM. Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery. Cancers. 2023;15(12):3220. doi:10.3390/cancers15123220

BibTeX
@article{Colombo2023,
  author = {Colombo, Ilaria and Karakasis, Katherine and Suku, Sneha and Oza, Amit M},
  title = {Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {12},
  pages = {3220},
  doi = {10.3390/cancers15123220}
}
Kostenlos starten →